• Explore /
  • Poster
  • / Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2−, <em>PIK3CA</em> mutant or wild-type, breast cancer (BC).

Phase II, randomized, placebo-controlled study of BYL719 or buparlisib (BKM120) with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2−, PIK3CA mutant or wild-type, breast cancer (BC).

Abstract Poster

Authors

Ingrid Mayer

Ingrid A. Mayer

Vanderbilt-Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN

Ingrid A. Mayer , Peter A. Fasching , Michael Gnant , Mario Campone , Lars Blumenstein , Anuradha Dutta , Caroline Germa , Rachel Li , Carlos L. Arteaga

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT01923168

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS655^)

DOI

10.1200/jco.2014.32.15_suppl.tps655

Abstract #

TPS655^

Poster Bd #

117B

Abstract Disclosures

Similar Posters

First Author: Ingrid A. Mayer

First Author: Nadia Harbeck

First Author: Angelo Di Leo

First Author: Sinead Toomey